News

Pembrolizumab is said to be the first drug to be approved in March through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS). The

The clinical trial had 60 pre-diabetic patients. This key developmental trial, being conducted in Hong Kong and the associated endpoints are pivotal for concluding the BTI-320 registration in

The primary efficacy endpoint is the summed pain intensity difference (SPID) over 1-hour (SPID1). Safety endpoints, such as adverse events and vital signs will also be assessed, as

The sNDAs can be used for the treatment of patients with chronic hepatitis C (HCV) coinfected with human immunodeficiency virus (HIV-1), patients with advanced cirrhosis (including decompensated cirrhosis),

The approval has been granted for TXA127 to reduce skeletal muscle damage and fibrosis, allowing to improve muscle strength in DMD patients. DMD is a genetic disorder that

A DFU is an open sore that affect the heel, toes, top, or bottom of the foot, which usually starts as a cut and can get bigger over

The company’s lead product candidate, enobosarm, is also being evaluated in a separate Phase II clinical trial to treat estrogen receptor positive (ER+), AR+ breast cancer. The open-label,

AmerisourceBergen president and CEO Steven Collis said: "The acquisition of PharMEDium strengthens our core business and meaningfully expands our innovative service offerings for health systems. "PharMEDium is a

The FDA has determined MPI’s Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL (1.25 g/5 mL vials) to be bioequivalent and, therefore, therapeutically equivalent to Delalutin Injection, 250 mg/mL